Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes
JAMA · 27.02.2024 · 331 (8) · 654
DOI: 10.1001/jama.2024.0318 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 27.02.2024. Verfasst von Anita P Courcoulas und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Bariatric Surgery, Diabetes Mellitus, Type 2, Gastric Bypass. Die Arbeit wurde bisher 290-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance Randomized clinical trials of bariatric surgery have been limited in size, type of surgical procedure, and follow-up duration.
Objective
To determine long-term glycemic control and safety of bariatric surgery compared with medical/lifestyle management of type 2 diabetes. Design, Setting, and Participants ARMMS-T2D (Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes) is a pooled analysis from 4 US single-center randomized trials conducted between May 2007 and August 2013, with observational follow-up through July 2022.
Intervention
Participants were originally randomized to undergo either medical/lifestyle management or 1 of the following 3 bariatric surgical procedures: Roux-en-Y gastric bypass, sleeve gastrectomy, or adjustable gastric banding. Main Outcome and Measures The primary outcome was change in hemoglobin A 1c (HbA 1c ) from baseline to 7 years for all participants. Data are reported for up to 12 years.
Results
A total of 262 of 305 eligible participants (86%) enrolled in long-term follow-up for this pooled analysis. The mean (SD) age of participants was 49.9 (8.3) years, mean (SD) body mass index was 36.4 (3.5), 68.3% were women, 31% were Black, and 67.2% were White. During follow-up, 25% of participants randomized to undergo medical/lifestyle management underwent bariatric surgery. The median follow-up was 11 years. At 7 years, HbA 1c decreased by 0.2% (95% CI, −0.5% to 0.2%), from a baseline of 8.2%, in the medical/lifestyle group and by 1.6% (95% CI, −1.8% to −1.3%), from a baseline of 8.7%, in the bariatric surgery group. The between-group difference was −1.4% (95% CI, −1.8% to −1.0%; P < .001) at 7 years and −1.1% (95% CI, −1.7% to −0.5%; P = .002) at 12 years. Fewer antidiabetes medications were used in the bariatric surgery group. Diabetes remission was greater after bariatric surgery (6.2% in the medical/lifestyle group vs 18.2% in the bariatric surgery group; P = .02) at 7 years and at 12 years (0.0% in the medical/lifestyle group vs 12.7% in the bariatric surgery group; P < .001). There were 4 deaths (2.2%), 2 in each group, and no differences in major cardiovascular adverse events. Anemia, fractures, and gastrointestinal adverse events were more common after bariatric surgery. Conclusion and Relevance After 7 to 12 years of follow-up, individuals originally randomized to undergo bariatric surgery compared with medical/lifestyle intervention had superior glycemic control with less diabetes medication use and higher rates of diabetes remission. Trial Registration ClinicalTrials.gov Identifier: NCT02328599
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Research Division, Joslin Diabetes Center, and Harvard Medical School, Boston, Massachusetts.
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
- Kaiser Permanente Washington Health Research Institute, Seattle.
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
- Department of Internal Medicine, Division of Physical Activity and Weight Management, University of Kansas Medical Center, Kansas City.
Förderung
- NIDDK NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Courcoulas, A. P., Patti, M. E., Hu, B., Arterburn, D. E., Simonson, D. C., Gourash, W. F., Jakicic, J. M., Vernon, A. H., Beck, G. J., Schauer, P. R., Kashyap, S. R., Aminian, A., Cummings, D. E., & Kirwan, J. P. (2024). Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. JAMA, 331(8), 654. https://doi.org/10.1001/jama.2024.0318
Vancouver
Courcoulas AP, Patti ME, Hu B, Arterburn DE, Simonson DC, Gourash WF, et al. Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. JAMA. 2024;331(8):654. doi:10.1001/jama.2024.0318
BibTeX
@article{Courcoulas2024,
author = {Courcoulas, Anita P and Patti, Mary Elizabeth and Hu, Bo and Arterburn, David E and Simonson, Donald C and Gourash, William F and Jakicic, John M and Vernon, Ashley H and Beck, Gerald J and Schauer, Philip R and Kashyap, Sangeeta R and Aminian, Ali and Cummings, David E and Kirwan, John P},
title = {Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes},
journal = {JAMA},
year = {2024},
volume = {331},
number = {8},
pages = {654},
doi = {10.1001/jama.2024.0318}
}
EUVIMED